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effect. Cardio-cerebrovascular diseases (CCVD) are a leading cause of death. TCM is used in
China to prevent and treat CCVD. However, the complexity of TCM poses challenges in under-
standing the mechanisms of herbs at a systems-level, thus hampering the modernization and
globalization of TCM. A novel model, termed traditional Chinese medicine systems pharma-
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integrates absorption, distribution, metabolism, excretion and toxicity (ADME/T) evaluation,
target prediction and network/pathway analysis, was proposed to address these problems.
Here, we review the development of systems pharmacology, the TCMSP approach and its
applications in the investigations of CCVD and compare it with other methods. TCMSP assists
in uncovering the mechanisms of action of herbal formulas used in treating CCVD. It can also
be applied in ascertaining the different syndrome patterns of coronary artery disease, decod-
ing the multi-scale mechanisms of herbs, and in understanding the mechanisms of herbal
synergism.
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Cardiovascular and cerebrovascular diseases (CCVD),
including thrombosis, stroke, myocardial infarction, coro-
nary heart disease, and high blood pressure, continue to
pose a threat to human health. In 2008, approximately 17.3
million people died of cardiovascular diseases worldwide,
of which an estimated 7.3 million deaths were due to cor-
onary heart disease and 6.2 million deaths were due to
stroke.1 Given the high incidence and high mortality of
CCVD, seeking feasible prevention and treatment strategies
is highly imperative and critical to human health. Conven-
tional drug therapies include blood pressure-lowering
medications, such as diuretics, angiotensin-converting
enzyme (ACE) inhibitors or beta blockers, blood-thinning
medications (to reduce platelet aggregation), cholesterol-
lowering medications, and/or anti-arrhythmic medica-
tions.2 Although these drugs have played great therapeutic
roles, most produce unwanted side effect, such as flushing,
fatigue, shortness of breath, headache, dizziness from
some antihypertensives,3 as well as rhabdomyolysis and
hepatic diseases from hypolipidemic agents.4
Traditional Chinese medicine (TCM) has attracted
extensive attention for its ability to treat complex diseases
due to its moderate treatment effect and lower side effect.
There is growing recognition in the West that TCM, char-
acterized by multiple compounds and multiple biological
targets, is more effective than single drug remedies,
especially for the treatment of complex chronic disorders
such as schizophrenia, depression, diabetes, as well as
cardiovascular diseases.5 Despite the empirical efficacy and
safety of TCM, there is still a lack of appropriate methods to
explore the specific constituents in a particular herb when
treating a disease and the biological factors that determine
the herb’s effectiveness.
Traditional pharmacology regards the cellular and
tissue/organ-level systems as a black box, thus leading to a
lack of mechanistic understanding of drug actions (phar-
macodynamics) and the failure in clinical trials of most new
drugs. Lack of drug mechanism understanding also means
the inability to predict the adverse effects of drug, which
has led to the withdrawal of or tight restrictions on the use
of many drugs.6 Systems pharmacology has emerged as a
powerful tool to overcome these limitations by applying
systems biology principles to the pharmacology field. It aims
to reveal the dynamic interactions between drugs and the
biological system as a whole, rather than individual con-
stituents. Since there is some correlation between systems
pharmacology and TCM, systems pharmacology strategies
have been increasingly applied to explore the functional
mechanism of TCM for the treatment of CCVD. This in turn
has facilitated the discovery of novel effective drugs.7
In this review, we present an overview of systems
pharmacology including its definition, characteristics,
methods, and applications, as well as procedures to inte-
grate it with current TCM research. Latest advances and
application to CCVD are discussed to provide a new strategy
to guide clinical studies, as well as to determine the risk of
adverse drug effect for better treatment and control of
complex diseases. Challenges and future directions in this
field are also discussed.Traditional Chinese medicine systems
pharmacology (TCMSP) analysis platform
To fully understand drug pharmacodynamics, which in
essence reveals how complex diseases emerge, a quanti-
tative systems-level perspective is needed.8 The field of
systems pharmacology has made enormous progress in
addressing drug action at the organ and organism levels.
Systems pharmacology utilizes the concepts of systems
biology to reveal pharmaceutical actions and guide drug
discovery. Principal approaches for systems pharmacology
include information integration of omics data sets, com-
puter modeling, data analyses that focus on network
analysis, and a direct experimental approach.
For centuries, herbal medicines have been used for
health maintenance by every culture around the world.
TCM is the only ethnomedicine with an unparalleled num-
ber of herbal formulas e nearly 50 000.9 The diversity of
components in each formula limits not only the extraction
of the active ingredients of the herbs, but also the analyses
of their pharmacologic mechanisms, and the identification
of potential targets of the chemical constituents. To meet
this challenge, a comprehensive systems-based approach
that can simultaneously prioritize all active ingredients and
their targets in the crude drug is needed.
Traditional Chinese medicine systems pharmacology
(TCMSP) analysis platform is a set of novel and innovative
approaches that has been proposed to develop a method-
ology for screening active herbal constituents, identifying
drug targets, and investigating the relationship between
active constituents and diseases.10 Using this platform, a
fundamental pharmacokinetics-pharmacodynamics theory
for TCM can be constructed. The core of TCMSP is a series
of integrated mathematical and computational models
that are applied to efficiently explore the interactions
among different elements (herbal compounds, drug tar-
gets, cells, tissues) and to reveal the functional mecha-
nism of TCM theories. Its ultimate goal is to facilitate drug
discovery and development as well as disease prevention
and treatment.
Construction of the TCMSP framework begins with large-
scale data mining from the literature and various databases
to collect chemical, genomic and pharmacologic informa-
tion on herbs and their corresponding constituents, fol-
lowed by statistical analyses of the information (Fig. 1). To
screen the promising active components, in silico models
are established to predict the absorption, distribution,
metabolism, excretion, and toxicity (ADME/T) properties of
the chemicals. Then drug targeting, performed by applying
an integrated model, is used to predict the multiple com-
poundeprotein interactions.11 The interactions are then
verified by other databases, the literature, and/or molec-
ular dynamics simulations. Finally, the networks, including
drug-target, drug-pathway, and drug-disease are generated
and analyzed to form herb-disease-organism associations.12
ADME/T evaluations
ADME/T evaluations of drugs are critical procedures in drug
discovery and development. The past years have witnessed
advances in combinatorial chemistry and high throughput
Figure 1 Construction of the TCMSP framework.
86 Y. Fu et al.medicinal chemistry software, which can screen large
numbers of compounds.13 A typical example is Chinese
herbs, many of which contain up to 50 species and thou-
sands of chemical compounds, but only a few compounds
exhibit favorable ADME/T properties with potential bio-
logical effect.14 Hence, there is an urgent demand for
ADME/T assessment of the effect or risks of these herbal
ingredients on the human body. However, ADME/T
screening and analysis of bioactive components remain
challenging because conventional experimental approaches
involving separation, purification, and structure elucidation
must still be used to obtain ADME/T properties of drugs.7,15
These processes are time-consuming, laborious, and costly,
and as such are limited in scope.
With the increase in computer processing power, in sil-
ico methods are being successfully applied to ADME/T
prediction for drugs.16,17 In silico ADME/T prediction is
composed of molecular modeling and data derived
modeling (data modeling).18e20 Data modeling methods are
used to efficaciously screen crucial compounds in
herbs.21e24 One model is the human oral bioavailability
(OB) prediction expert system,25 which integrates P-glyco-
protein (P-gp) and cytochrome P450s into the construction
of QSAR modeling based on hundreds of structurally diverse
drugs and drug-like molecules. OB is defined as the rate and
extent to which the active ingredient or active moiety is
absorbed from a drug product and becomes available at the
site of action.25 As a subcategory of absorption, OB is one of
the most common pharmacokinetic parameters in drug
screening cascades, since the main reason for stopping
further development of drug candidates is often the low
and highly variable bioavailability of potential drugs.25 The
blood brain barrier (BBB), which separates the brain and
central nervous system (CNS) from the bloodstream, is also
an important factor of concern in designing drug molecules.
In silico prediction of a compound’s ability to cross the BBB
will contribute to the screening of efficient small molecules
for treating brain diseases.26,27 Other important ADME-
related properties, such as Caco-2 permeability and Lip-
inski’s rule of five (MW, AlogP, TPSA, Hdon, Hacc), have also
been applied to active compound screening of herbal
medicines. Several in silico models have been developed
for the enzyme kinetics of cytochrome P450 3A4 (CYP3A4)28
and for predicting substrates and inhibitors of P-glycopro-
tein29 as well as toxicity of drugs.Target fishing
Target fishing is a useful tool to predict and validate drug
targets and toxin targets and to detect drug-target in-
teractions. However, even when the number of original
herbal compounds has been significantly reduced, the work
involved is still labor intensive due to the diversity of tar-
gets for each component and the fact that a single protein
may correspond to multiple components.30
To tackle this problem, in silico target fishing is an
emerging technology31,32 for predicting the biological tar-
gets of compounds on the basis of chemical structure
through the use of information from existing biologically
annotated chemical databases. Though public databases
have been established to store drug-target interactions,
including DrugBank,33 Matador,34 STITCH,35 and KEGG
DRUG,36 the interacting targets of the majority of small
molecules remain unknown, especially targets for natural
products extracted from Chinese herbs.
Currently, the most widely used target prediction
methods are based on structure, ligand, and text-mining.
Ligand-based methods (LBM) compare candidate ligands
with known drugs of a target protein to find new compounds
using statistical tools.37 Performance of LBM relies on the
number of known active molecules for a target. A drawback
of LBM is that it has difficulty in identifying drugs with novel
structural scaffolds that differ from the reference mole-
cules. Structure-based methods, such as molecule docking,
are constrained by available crystallographic structures of
the target. Text mining, on the other hand, can uncover
information that already exists in the literature but has
been missed. But the inability to detect new biologic find-
ings and the redundancy of the compound and gene names
in the literature have hampered the efficiency of text
mining approach.38 In addition, a chemogenomics-guided
target-ligand approach combines the ligand chemical
space, target space and the currently known drug-target
networks information to construct a complex forecast sys-
tem, with purpose of predicting the ligands or targets for a
given ligand or target without prior attempts to define a
special set of similar receptors or ligands.39 Previously, we
have also constructed a systematic prediction model, which
efficiently integrated chemical, genomic, and pharmaco-
logic information on a large scale, supported by heteroge-
neous biologic data. This model has been successfully
Figure 2 Application of TCMSP to CCVD mechanism and
management.
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pounds in herbal medicines.11
Network analysis
Advances in genomics, biochemistry, molecular and cell
biology, and physiology have allowed initial glimpses of the
complexity of human biology at the atomic/molecular,
cellular and tissue, organ, and organismal levels. Network
analysis is a useful approach for multi-scale understanding
of the organization of interactions among the components
of a system.6 Network analysis can be used to reveal the
associations between topology structures and biological
functions at each level and interactions between levels that
come into being organ- and organismal-level functions.
Understanding the specific functional connections between
multi-scales of organization contributes to the interpreta-
tion of how drugs interact with molecular targets and how
their initial effects at the cellular level produce thera-
peutic or adverse effects at the final organ and organismal
levels.6
In this context, from a network perspective, network
pharmacology aims to investigate drug intervention or ef-
fect to address the synergism of multicomponent drugs and
to screen and develop highly efficient and low toxicity
multi-target drugs.40,41 Network pharmacology is consistent
with Chinese herbal medicines and has been successfully
applied to discovering effective components and eluci-
dating the pharmacologic mechanisms of herbs.42 Thus, it
offers a new framework for drug discovery by attacking the
pathology network at the systems level rather than by
focusing on individual components. Limitations of this
approach include the integrity and accuracy of existing
data, as well as the insufficient experimental validations of
the constructed model. Nevertheless, interesting findings
have been reported, showing that through network anal-
ysis, topologic properties are bridged with functional fea-
tures of herb-disease connections, thus elucidating
therapies and serving as a guide for drug application.43,44
Application of TCMSP to CCVD
CCVD is a series of diseases caused by many factors,
including genetic, physical/chemical, environmental, and
psychologic.7 In China, CCVD has been treated with herbs or
herbal combinations for many years. Two such remedies are
Compound Danshen Formula (CDF) and Radix Curcumae
Formula (RCF). However, the underlying mechanisms of the
herbs and formulas remain unknown. This has greatly
hampered their modernization and globalization. These
two formulas are comprised of multiple herbs and have
great advantage over single agents, which may not be able
to surmount the inherent characteristics of the disease
system they are intended to treat. Studies using TCMSP
have attempted to predict the potential targets of the
herbs in the formulas and uncover the mechanisms of ac-
tion of the active ingredients,7,14 so as to give novel pos-
sibility on how to treat CCVD. For example, Wang et al.45
applied systems biology to understanding the pharmaco-
logic synergy in CCVD herbal formulas and discovered
potent drug/herb combinations that are individuallysubtherapeutic. Zhou and Wang24 used systems pharma-
cology to dissect the different TCM patterns of coronary
artery disease (CAD) to explore combining Chinese herbs
with pharmaceutical drugs to treat CCVD. Other studies
have also attempted to decode the multi-level mechanisms
of herbs for treatment and prevention of stroke.46,47 Thus,
application of TCMSP to CCVD may provide new perspective
on the management of CCVD (Fig. 2).
Chinese herbal formulas for CCVD treatment
Traditional Chinese herbal formulas (fu fang, or fang ji)
have been used in China for millennia and are typically
comprised of several herbs. Rather than an arbitrary com-
bination of herbs, they are prescribed based on TCM theory,
specifically the hierarchy principle of chief, deputy, assis-
tant, and envoy (jun, chen, zuo, shi)48,49 and follow the
rule of drug compatibility and combination. Several TCM
formulas, such as CDF and RCF, have been extensively
implemented in the treatment of CCVD with beneficial
effects.
CDF is listed in the Pharmacopoeia of the People’s
Republic of China (PPRC).50 The formula is comprised
primarily of three ingredients: salvia (Salvia miltiorrhiza
Bge.), notoginseng root (Panax notoginseng (Burk.)), and
borneol (Borneolum; crystallized resin and volatile oil of
Cinnamomum camphora (L.) J. Presl), at a ratio of
450:141:8 (grams).50 Clinical studies have shown desirable
pharmacologic effect of CDF on CCVD, including dilating
coronary vessels (which increases coronary flow rate) and
activating superoxide dismutase.51e53 Studies have also
shed light on the underlying molecular mechanisms of
CDF. For example, a network pharmacology study of major
active compounds of CDF found that tanshinone IIA, sal-
vianolic acid B, protocatechuic aldehyde, danshensu,
cryptotanshinone, notoginsenoside R1, ginsenoside Rg1,
ginsenoside Rb1, and borneol could modulate dozens of
CCVD-associated genes that correspond to different dis-
eases, which suggests new potential indications of CDF.54
Zhang et al.55 used metabolomics to investigate the
therapeutic and synergistic effect of three major active
ingredients (tanshinone IIA (T), salvianolic acid B (S) and
ginsenoside Rb1 (G)) of CDF in the rat model of myocardial
ischemia (MI). Results suggested that TSG has nearly equal
88 Y. Fu et al.therapeutic effect on MI as the formula itself, and has a
more stable regulated action on several specific metabo-
lites than a single compound alone.55 Limitation of these
studies is that they only focused on a portion of the active
ingredients and were not able to provide a systems-level
understanding of how the diverse chemical components
in CDF contribute to the overall pharmacologic effect of
the herbs on CCVD. Under a systems pharmacology
framework, we performed a high-throughput in silico
screening and obtained a group of compounds from CDF
that possess desirable pharmacodynamic and pharmaco-
logic characteristics. These compounds and corresponding
protein targets were further used to search against bio-
logic databases, such as compound-target associations,
compound-pathway connections, and diseaseetarget in-
teractions for reconstructing biologically meaningful net-
works for CDF.14
RCF is another formula listed in PPCR.50 It is comprised
of four ingredients: curcuma tuber (Curcuma longa L.),
cape jasmine fruit (Gardenia jasminoides Ellis), musk
(Moschus; navel gland secretion of the musk deer), and
borneol. RCF is another effective remedy that has been
widely used in China to prevent CCVD.56 Animal and human
studies have demonstrated that RCF acts directly on the
central nervous system through the blood brain barrier to
reduce brain injury and enhance functional recovery after
traumatic brain injury (TBI) and stroke. TCMSP analysis
identified dozens of bioactive ingredients in RCF and po-
tential targets related to CCVD.7 Results indicate that
curcuma tuber shares the most common targets with cape
jasmine fruit, and fewer common targets with musk and
borneol. Further integrated networking shows that curcuma
tuber is the principal component in the prevention of CCVD
and the three other ingredients serve as adjuvants, syner-
gistically assisting the effect of the principal component.
These studies provide a clue for understanding the
compatible mechanisms of complex prescriptions such as
CDF and RCF and offer an alternative approach to investi-
gate novel TCM formulas for CCVD treatment.Exploration of syndrome definition of CAD
CAD is one of the most common CCVD. CAD leads to
sequelae such as myocardial infarction and heart failure
and is the leading cause of mortality and disability world-
wide.57 Conventional therapies for CAD are pharmaceutical
drugs, lifestyle changes, surgery, and other interventions.
TCM, on the other hand, combats CAD with thousands of
herbal prescriptions as well as other traditional
modalities.58
TCM is substantially different from the reductionism
approach of Western medicine. TCM uses a holistic
approach and focuses on the aggregate observation of signs
and symptoms to describe the patient’s body as a whole,
using patterns or syndromes (zheng).24 In TCM, CAD can be
classified into different TCM syndromes: blood stasis, qi
deficiency, phlegm-turbidity, cold coagulation, yin defi-
ciency, and yang deficiency,59 of which the three main
syndromes are blood stasis, qi deficiency, and phlegm-
turbidity.60 Modern methods are being used to study CAD
syndromes. Lu et al.61 applied SVM feature selection andBayesian network classifiers to proposing an in silico
method to predict six syndromes of CAD, which may
improve treatment.61 Shi et al.62 applied complex
networking and chi-squared automatic interaction detector
(CHAID) decision tree methodology to identify core TCM
syndromes of CAD and established TCM syndrome identifi-
cation modes of CAD based on biologic parameters. Wang
et al.63 analyzed two-dimensional electrophoresis results of
blood samples of CAD patients and found 10 inflammatory
factor proteins associated with blood stasis syndrome. They
also proposed an unsupervised pattern-discovery algorithm
to detect the significantly associated patterns, which
resulted in the discovery of the association between CAD
syndrome and proteome.
In our work, we analyzed the underlying mechanism of
different CAD syndromes (mainly the blood stasis and qi
deficiency syndromes), by using systems pharmacology to
explore the complicated diseaseesyndrome correlation and
established a diagnostic process at microcosmic level.24 We
found that herbs for eliminating blood stasis are capable of
dilating blood vessels, improving microcirculation, reducing
blood viscosity, and regulating blood lipids, while qi-
enhancing herbs promote energy metabolism and anti-
inflammation. These studies bring perspective to the inte-
gration of TCM and Western medicine and the combination
of TCM with Western drugs to form an integrative/alter-
native medicine for the treatment of complex diseases such
as CAD.Herbal synergy and new herb combinations for
treating CAD
Empirical use and clinical trials have shown that several
herbs combined in a single formula are more efficacious
than single herbs.64 For instance, the pharmacologic effect
of one herb as an ingredient of a single formula can be
strengthened, extended, or its side effect suppressed by
the other herbal ingredients. Thus, the therapeutic effect
of multi-herb formulas likely arise from the synergistic ac-
tions of the combined herbal ingredients.65 For example, it
has been reported that saponins increase the absorption of
corticosteroids and procyanidin B2 or hyperoside increases
the solubility of hypericin.66,67 Several studies have focused
on the underlying mechanisms of such multicomponent
synergies associated with interacting targets, pathways,
and diseases. In our work, we applied TCMSP to investi-
gating the synergistic mechanisms of four widely used herbs
for cardiovascular disease treatment: astragalus (Astraga-
lus membranaceus), kudzu (Puerariae lobata (Willd.)),
ophiopogon tuber (Ophiopogon japonicus (Thunb.) Ker-
Gawl.), and salvia (Salvia miltiorrhiza Bge.).45 Results
found that the structural properties of molecules in the
four herbs had substantial differences and the interactions
of individual compounds in each herb with target proteins
may be different, although the pharmacologic properties of
the four herbs were quite similar in the treatment of CVD.
The actions of different herb pairs may show mutual
enhancement to exert a complementary synergistic effect
in different modes.
Another study also applied systems pharmacology to the
discovery of new herb/drug combinations. Relevant
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CVD-associated target space was utilized to screen effec-
tive herbal molecules.68 Biologic network analysis and
experimental validation were then applied to discovering
novel herb combinations. Experimental validation of one
optimal herb combination Dan Shan Hong (DSH), which is
comprised of salvia (Salvia miltiorrhiza Bge.), hawthorn
fruit (Crataegus pinnatifida Bge.), and safflower (Cartha-
mus tinctorius L.), showed that treatment with DSH
improved myocardial function and mRNA expression levels
of CVD-associated targets in the mouse model of myocar-
dial infarction.68 Research such as the aforementioned not
only deepen the understanding of the pharmacologic syn-
ergy in herbal medicines, but also strengthen the founda-
tion for the rational discovery of potent drug/herb
combinations.Multi-scale mechanisms of herbs in stroke
treatment and prevention
Stroke, also referred to as cerebrovascular accident (CVA),
is the second most common cause of cerebrovascular death
worldwide69 and can lead to irreversible neurologic dam-
age or even death. Each year there are around 16 million
persons who have first-ever strokes and 6.2 million deaths
due to stroke.70 Treatment and prevention with medica-
tion are not ideal due to diverse risk factors, such as old
age, hypertension, previous stroke or transient ischemic
attack, diabetes, hyperlipidemia, smoking, and atrial
fibrillation.71 The gains in molecular neuroscience have
resulted in life-saving therapies. Nevertheless, the de-
mand for continued development of pharmacologic treat-
ment of stroke remains urgent. For example, intravenous
thrombolytic therapy with recombinant tissue plasminogen
activator (rtPA) has been demonstrated to be an effective
treatment for ischemic stroke. But its application is limited
in that it can only be applied within 3e4.5 hours of
ischemic stroke onset, and it cannot benefit hemorrhagic
stroke patients. Thus, rtPA therapy is limited to only 1%e
2% of all stroke patients.72 Thus, there are still very few
effective biomedical interventions available for the ma-
jority of stroke patients.
In China, however, a large number of herbs have been
used to treat stroke. Representative herbs include salvia
(Salvia miltiorrhiza Bge.), gingko leaf (Ginkgo biloba L.),
ephedra (Ephedra sinica Stapf.), and lifeflower (Erigeron
breviscapus (Vant.) Hand.eMazz.). Some of these herbs or
their related products have been shown to have desirable
pharmacologic activities for stroke treatment, such as
possession of neuroprotective effect, or the ability to dilate
cerebrovascular vessels to improve brain microcirculation,
inhibit platelet aggregation, as well as augment hypoxia
tolerance of brain cells.73,74 Other studies have also been
carried out to explore the molecular mechanisms of anti-
stroke herbs. For example, Bei et al.47 revealed the un-
derlying mechanism of the TCM drug Nao Xin Qing (NXQ), an
extraction from the leaves of Japanese persimmon (Dio-
spyros kaki L. Dispryosl and Ebenceae). NXQ was found to
be capable of alleviating cell injury and apoptosis in vitro
and improving redox imbalance in cells under exposure of
H2O2. Sucher’s work on 58 TCM herbs for stroke revealedthat by binding to different molecular targets the drugs
exert functions in signaling pathways involved in N-methyl-
D-aspartate (NMDA) receptor-mediated neuronal injury and
death. In addition, the purification of those single chemical
compounds from TCM interacting with these targets was
also performed.72
Recently, using a combined modified systems-
pharmacology method with pathway analysis, we were
able to dissect the multi-scale mechanisms of several anti-
stroke herbal medicines to improve the management of
cerebral stroke.46 A list of medicinal herbs that exhibited
notable correlations with stroke was obtained by large-
scale text mining of the PubMed database. Results
showed that anti-stroke herbal medicines could produce
anti-inflammation, anti-oxidant, and anti-apoptosis effect
against ischemic brain damage, and exert lipid-lowering,
anti-diabetic, anti-thrombotic, and antiplatelet effect
and simultaneously target several related pathways, thus
exhibiting potential therapeutic benefits in stroke treat-
ment and prevention.46Discussion and conclusions
Traditional Chinese herbs hold great promise for treating
and preventing complex diseases in an integrative and ho-
listic way. However, understanding the pharmacologic
mechanisms of herbs at a systems-level remains a chal-
lenge. The new field of systems pharmacology, which fo-
cuses on the quantitative analysis of the dynamic
interactions between drugs and a biological organism, has
brought hope in meeting this challenge. Based on the the-
ory of systems pharmacology, we proposed the concept of
traditional Chinese medicine systems pharmacology, and
constructed a novel model for the study of herbal drugs,
their targets and effect, which not only involves the
application of systems biology approaches, but also is in-
tegrated with pharmacokinetic and pharmacodynamic
evaluations. Application of TCMSP to CCVD research will
help uncover the mechanisms of action of herbal formulas
used to treat and prevent cardio-cerebrovascular diseases,
and to exploring the syndrome types of coronary artery
disease, as well as to understanding the mechanisms of
herbal synergism.
In current drug discovery and drug development,
network pharmacology is a cutting-edge field. Its studies
emphasize the paradigm shift from “one target, one drug”
to “network target, multicomponent therapeutics” high-
lighting a holistic thinking which is also shared by TCM.75
Applying network pharmacology to Chinese herbal
research may give impetus to the discovery of bioactive
ingredients and endogenous/exogenous biomarkers, and in
revealing mechanisms of action and exploring the scientific
basis of numerous Chinese herbs and herbal formulas.
However, network pharmacology falls short in its ability to
investigate drug metabolism, pharmacokinetics, and
toxicity of herbs. Systems pharmacology, integrating ADME/
T evaluation and pathway/network analyses, makes up for
network pharmacology’s shortcomings.
When challenged by pressure to develop new drugs as
rapidly as possible, conventional methods usually fail. This
can be attributed partly to the lack of understanding of the
90 Y. Fu et al.multi-scale mechanisms. TCMSP, on the other hand, has
impacted the development and usage of herbal drugs. Thus,
with the evolution of systems biology andmedicine, the pace
of drug development will gradually catch up with the
explosion in scientific knowledge. In addition, continuous
updating of the TCMSP analysis platform will raise the accu-
racy of the ADME/T virtual screening model, the compound-
target interaction prediction model, and the integration of
different levels of omics data and clinical information.
Looking to the future, TCMSP may also be applied to
other complex diseases, such as rheumatoid arthritis, dia-
betes, and cancer. A strong research platform specializing
in the pharmacologic mechanisms of the herbal medicines
that treat these diseases, and combined application of
systems pharmacology with modern scientific methods,
such as the omics and informatics, will be a powerful tool to
uncover the scientific value of Chinese herbal medicines,
and to explore their application in new drug development.
Such further investigations will undoubtedly facilitate the
development, exploration, and exploitation of Chinese
herbal medicine, as well as the modernization of TCM.Acknowledgments
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